Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CB-012 by Caribou Biosciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval
CB-012 is under clinical development by Caribou Biosciences and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Data Insights
CB-012 by Caribou Biosciences for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
CB-012 is under clinical development by Caribou Biosciences and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...